Medical Technology company Marizyme, Inc. highlights its flagship product, DuraGraft®.
Jun 15, 2023 at 12:00 PM
Marizyme, Inc. (OTCQB:MRZM) is a medical technology company dedicated to the accelerated development and commercialization of devices that improve patient outcomes. This MedTech company has achieved several milestones and looks to complete many more in 2023.
Marizyme’s flagship product, DuraGraft®, continues to make impressive strides in the cardiac surgery industry and is generating revenue internationally in countries including Spain, the Philippines, Germany, Switzerland, Singapore, Malaysia, Turkey, Ireland, Austria, and the UK. Building on their international success, Marizyme is now looking to enter the US market. According to a business update provided by the Company on May 5, 2023, DuraGraft is currently under review by the FDA for authorization in the United States.
The Company also continues to strengthen the IP around DuraGraft®, with patents recently granted in the United States, India, South Korea, and Vietnam. Additional patent applications have been allowed in Canada and Vietnam. For more information on DuraGraft’s IP, and Marizyme’s other related technologies, please refer to their latest news release:
Marizyme Announces IP Developments for DuraGraft and Its Pipeline Products
Current Landscape of CABG Surgery
Coronary Artery Bypass Graft (CABG) surgery is the most common cardiac surgery in the world with over 1 million CABG procedures performed annually worldwide.(1) With an estimated 500,000 procedures performed annually in the US alone, expansion into the US market is essential, and Marizyme is well positioned to take a piece of the ~$16.1 billion market.(2)(3)
During CABG surgery, bypass grafts are used to re-route blood around blockages in native coronary arteries. The types of grafts used are most often the patient’s own vessels. It is important to remember that the new graft (vein/artery) is alive and fragile. It deserves the same protection and treatment as any other tissue or organ being transplanted.
DuraGraft® is a first-in-class CE marked intra-operative graft storage and flushing solution used during coronary artery bypass graft surgeries. DuraGraft is authorized for use in Europe and other counties outside of the United States, DuraGraft is not yet authorized for use in the United States.
Pipeline Products
Marizyme seeks to be an innovator to address unmet clinical needs in plastic and reconstructive surgery — specifically fat grafting. Fat grafting is a surgical process used in medical reconstructive and other plastic surgery procedures in which fat is transferred from one area of the body to another (known as “autologous fat grafting” or simply “fat grafting”) to correct a defect, replace injured tissue, or to make cosmetic enhancements. MAR-FG-001 is formulated as a tumescent solution base that protects adipose tissue during adipose tissue harvesting and storage.
The global market for autologous fat grafting was estimated to be $699.96 million in 2021 and is projected to grow at a CAGR of 8.62% until 2028 (“Global Autologous Fat Grafting Market – Industry Trends and Forecast to 2028,” Data Bridge Market Research December 2020).
According to Data Bridge Market Research, the global market for autologous fat grafting was estimated to be $699.96 million in 2021 and is projected to grow at a CAGR of 8.62% until 2028. With 22.4 million plastic surgeries performed annually in the United States(4) there is potential for widespread implementation of innovative fat grafting systems.
MATLOC™, a second pipeline product currently under development has been designed for the screening and diagnosing of chronic kidney disease (CKD) at point-of-care. In the US, about 37 million people have CKD and approximately 80 million people are at risk for developing it. But the majority (90%) who have this chronic condition are not even aware of it, according to the CDC. MATLOC will increase testing, early detection, and continuous monitoring of CKD and its progression to facilitate timely therapeutic and clinical intervention at an early disease stage when interventions can be effective in slowing disease progression.
In conclusion, Marizyme is a medical technology company with a strong focus on the commercialization of its flagship product, DuraGraft, supported by the development of its pipeline products. Marizyme provides a well-rounded opportunity – investors and medical professionals alike would be wise to keep a close eye on Marizyme’s progress and its potential impact on the global healthcare landscape.
To learn more about Marizyme, Inc., please visit their website at: click here.
[1] Weill Cornell Medicine. (2020, July 7). Method using artery for coronary artery bypass linked to better long-term outcomes than vein grafts. Weill Cornell Medicine Newsroom. https://news.weill.cornell.edu/news/2020/07/method-using-artery-for-coronary-artery-bypass-linked-to-better-long-term-outcomes-than
[2] HonorHealth. (n.d.). Coronary artery bypass grafting. HonorHealth. https://www.honorhealth.com/medical-services/cardiac-care/treatment-options/coronary-artery-bypass-grafting
[3] Mordor Intelligence. (2021). Coronary Artery Bypass Grafting Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026). Mordor Intelligence. https://www.mordorintelligence.com/industry-reports/coronary-artery-bypass-grafting-market
[4] American Society of Plastic Surgeons. (2020). Plastic Surgery Statistics Report. American Society of Plastic Surgeons.
https://www.plasticsurgery.org/documents/News/Statistics/2020/plastic-surgery-statistics-full-report-2020.pdf